Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Regeneron Pharmaceuticals, Inc.
  6. Summary
    REGN   US75886F1075

REGENERON PHARMACEUTICALS, INC.

(REGN)
  Report
Delayed Nasdaq  -  04:00 2022-12-07 pm EST
764.27 USD   +2.25%
12/07Replimune, Roche to Develop RP3 in Colorectal Cancer, Hepatocellular Carcinoma
DJ
12/02Insider Sell: Regeneron Pharmaceuticals
MT
12/02Insider Sell: Regeneron Pharmaceuticals
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2022 12/02/2022 12/05/2022 12/06/2022 12/07/2022 Date
761.24(c) 766.39(c) 755.45(c) 747.47(c) 764.27(c) Last
670 027 441 486 531 072 501 985 565 791 Volume
+1.27% +0.68% -1.43% -1.06% +2.25% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 11 937 M - -
Net income 2022 4 225 M - -
Net cash position 2022 5 788 M - -
P/E ratio 2022 20,2x
Yield 2022 -
Sales 2023 12 558 M - -
Net income 2023 3 957 M - -
Net cash position 2023 10 585 M - -
P/E ratio 2023 20,7x
Yield 2023 -
Capitalization 81 626 M 81 626 M -
EV / Sales 2022 6,35x
EV / Sales 2023 5,66x
Nbr of Employees 10 915
Free-Float 79,7%
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (65.5%); - supply of collaborative services (27.9%): working with Sanofi (50% of sales) and Bayer (50%); - sales of technology licenses (6.6%). The group also provides subcontracting research... 
Read more
Sector
Biotechnology & Medical Research
Calendar
12/08 | 03:35amPresentation
More about the company
Ratings of Regeneron Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about REGENERON PHARMACEUTICALS, INC.
12/07Replimune, Roche to Develop RP3 in Colorectal Cancer, Hepatocellular Carcinoma
DJ
12/02Insider Sell: Regeneron Pharmaceuticals
MT
12/02Insider Sell: Regeneron Pharmaceuticals
MT
12/02Regeneron esmo io presentations highlight potential of fianlimab and libtayo in multipl..
AQ
12/01Regeneron Pharmaceuticals - EVKEEZA SBLA FOR CHILDREN WITH ULTRA-RARE INHERITED FORM OF..
AQ
12/01Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo(R) in Mult..
CI
12/01Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplim..
PR
11/30Regeneron Pharmaceuticals' Evkeeza Accepted by US FDA for Priority Review
MT
11/30Evkeeza(R) (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High C..
CI
11/30Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cho..
PR
11/30Transcript : Regeneron Pharmaceuticals, Inc. Presents at Piper Sandler 34th A..
CI
11/29British Health Regulator Flags Risk Of Serious Eye Reactions To Sanofi-Regeneron's Asth..
MT
11/29Transcript : Regeneron Pharmaceuticals, Inc. Presents at 5th Annual Evercore ..
CI
11/28Insider Sell: Regeneron Pharmaceuticals
MT
11/22Regeneron Pharmaceuticals Obtains European Commission's Approval for Libtayo as Monothe..
MT
More news
News in other languages on REGENERON PHARMACEUTICALS, INC.
12/02Vente d'initiés : Regeneron Pharmaceuticals
12/01Les présentations de Regeneron à l'ESMO IO soulignent le potentiel de Fianlimab et Libt..
11/30L'Evkeeza de Regeneron Pharmaceuticals accepté par la FDA américaine pour une revue pri..
11/30Evkeeza(R) (evinacumab-dgnb) sBLA pour les enfants atteints d'une forme héréditaire ult..
11/29L'organisme britannique de réglementation de la santé signale le risque de réactions oc..
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on REGENERON PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
VanEck Vectors Biotech ETF - USD7.82%-1.38%United_States
Invesco Nasdaq Biotechnology ETF - USD7.68%0.80%-United_States
IShares Nasdaq US Biotechnology (D) - USD7.64%0.43%United_States
IShares Nasdaq US Biotechnology - USD7.64%0.29%United_States
IShares Biotechnology ETF - USD7.27%-1.76%-NC
More ETFs positioned on REGENERON PHARMACEUTICALS, INC.
Analysis
Sanofi sees faster profit growth on Dupixent, flu vaccine
Chart REGENERON PHARMACEUTICALS, INC.
Duration : Period :
Regeneron Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 764,27 $
Average target price 795,83 $
Spread / Average Target 4,13%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS, INC.18.36%81 626
VERTEX PHARMACEUTICALS41.99%80 039
BIONTECH SE-37.31%39 277
WUXI APPTEC CO., LTD.-33.48%32 589
GENMAB A/S23.38%29 957
ARGENX SE18.17%21 685